Minimal Residual Disease Testing Market

Minimal Residual Disease Testing Market Growth Size by Technology (PCR, Flow Cytometry, NGS), Application (Leukemia, Lymphoma, Solid Tumors), End User (Hospitals, Specialty Clinics, Diagnostic Labs, Research and Academic Institutes) & Region - Global Forecast to 2027

Report Code: MD 8516 Dec, 2022, by marketsandmarkets.com

The global size of minimal residual disease testing market in terms of revenue was estimated to be worth USD 1.2 billion in 2022 and is poised to reach USD 2.3 billion by 2027, growing at a CAGR of 14.0% from 2022 to 2027. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Market is driven by the rising incidence and prevalence of cancer and hematological malignancies.

Minimal Residual Disease Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Minimal Residual Disease Testing Market Dynamics

Driver: Rising incidence of hematological malignancies

Over the years, the incidence of hematologic cancer has increased significantly, which includes leukemia and lymphoma. According to the Leukemia & Lymphoma Society 2020-2021, an estimated 1,519,907 people in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPNs). Also, the rising geriatric population across the globe is also a key factor supporting the increasing incidence of hematologic malignancies, as this population segment is more prone to various chronic diseases. Such cancer patients require continuous monitoring of disease during treatment. Also, the monitoring of minimal residual diseases (MRD) has become a routine clinical practice post-cancer treatment. As a result, the preference for minimal residual disease testing will likely rise in the forecast period, proportional to the growth in cancer prevalence.

Restraint: Complex regulatory framework and high cost of minimal residual disease testing kits

Regulatory and legal requirements applied to minimal residual tests are becoming more stringent.  The FDA requirements and the time required to obtain premarket approval have increased, particularly regarding 510(k) applications with the FDA facing challenges when there is no standardized method for an analyte. On the other hand, the implementation of minimal residual disease testing products in diagnostic laboratories requires high capital investments. For instance, the cost of advanced minimal residual disease testing products varies between USD 20,000 and USD 50,000. In developing countries such as India and Brazil, owing to budget constraints, small and medium-sized organizations and academic laboratories cannot afford advanced and high-priced MRD kits. These factors restrain the market growth.

Opportunity: Growth opportunities in minimal residual disease testing in emerging countries

Developing economies such as India, South Korea, Brazil, Turkey, Russia, and South Africa are expected to offer potential growth opportunities for major players operating in the market. This can be attributed to the rising geriatric population, the growing incidence of hematologic cancers, rising health expenditure per capita, and improving healthcare infrastructure. In addition to the factors mentioned above, the Asia Pacific region has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

Challenge: Unclear reimbursement scenario and policies for patients

The procedure of paying for pricey molecular testing and the knowledge of the several specialists needed to interpret test results and create treatment programmes are convoluted and even. This is particularly problematic with more expensive modern methods like liquid biopsy which also includes testing minimal residual disease. The price of molecular testing services is frequently unknown to doctors, pathologists and patients until they are paid or billed. This results in a confusion between the patients and the providers.

Additionally, payers’s biomarker coverage policies have complex organizational structures that are quite challenging to comprehend. While some only pay for the most fundamental testsor those related to certain clinical disordersand genes, others pay for a wide variety of testing. Due to significant variety, it is also very difficult to evaluate and keep track of different coverage policies.

The PCR segment accounted for the highest growth rate in the minimal residual disease testing industry, by technology, during the forecast period

The minimal residual disease testing market is segmented into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS). The PCR segment accounted for the highest growth rate in the market. The main elements contributing to the substantial proportion of this segment are the device’s simplicity of use, the accessibility of test kits and a better degree of sensitivity.

Hematological Malignancies applications segment of minimal residual disease testing industry, accounted for the highest CAGR

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. The hematological malignancies application segment accounted for the largest share. Leukemia, lymphoma and their various sub-types are becoming very common, and people are becoming more aware of the importance of ongoing patient monitoring, all of which are factors supporting the expansion of this market.

Hospitals & specialty clinics segment to dominate the minimal residual disease testing industry

Based on end users, the minimal residual disease testing market has been segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users. The hospitals & specialty clinics segment accounted for the largest share of this market, while diagnostic laboratories are growing at the highest rate. The presence of cutting-edge diagnostic tools and qualified specialist to conduct these tests is what accounts for the big share of this market.

North America is the largest region in the minimal residual disease testing industry for liquid biopsy

Growth in the developed markets of North America is primarily driven by The large share of this regional segment can be attributed to the significant increase of leukemia and lymphoma, highly developed healthcare culture in the US and Canada, the presence of numerous top national clinical laboratories, and the easy accessibility to cutting-edge technology.

Minimal Residual Disease Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some of the key players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US).

Scope of the Minimal Residual Disease Testing Industry

Report Metrics

Details

Market Revenue in 2022

$1.2 billion

Projected Revenue by 2027

$2.3 billion

Revenue Rate

14.0% CAGR

Market Driver

Rising incidence of hematological malignancies

Market Opportunity

Growth opportunities in minimal residual disease testing in emerging countries

This report categorizes the minimal residual disease testing market to forecast revenue and analyze trends in each of the following submarkets:

By Technology

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other Technologies

By Application

  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Solid Tumors
  • Other Applications

By End User

  • Hospitals and Specialty Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments of Minimal Residual Disease Testing Industry

  • In February 2019, Bio-Rad Laboratories, Inc. (US) announced the launch of the first FDA-cleared digital PCR system and test for monitoring chronic myeloid leukemia treatment response.In May 2022, QIAGEN N.V. (Netherlands) launched the therascreen EGFR Plus RGQ PCR Kit, a new in vitro diagnostic test for sensitive EGFR mutation analysis.
  • In August 2022, Roche launched the Digital LightCycler System, the company’s first digital polymerase chain reaction (PCR) system. This next-generation system detects diseases and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
  • In February 2021, Guardant launched the Guardant Reveal Liquid Biopsy Test for residual disease and recurrence monitoring in patients with early-stage colorectal cancer.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 25)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKETS COVERED 
           1.3.1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Primary sources
                    2.2.2.2 Key data from primary sources
                    2.2.2.3 Key industry insights
                    2.2.2.4 Breakdown of primary interviews
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation
                                FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 6 MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE 
    2.6 STUDY ASSUMPTIONS 
    2.7 GROWTH RATE ASSUMPTIONS 
    2.8 RISK ASSESSMENT 
           2.8.1 RISK ASSESSMENT: MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 41)
    FIGURE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2022 VS. 2027 (USD MILLION)
    FIGURE 9 MARKET, BY APPLICATION,  2022 VS. 2027 (USD MILLION)
    FIGURE 10 MARKET, BY END USER,  2022 VS. 2027 (USD MILLION)
    FIGURE 11 MARKET, BY REGION,  2022 VS. 2027 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 44)
    4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW 
          FIGURE 12 RISING INCIDENCE OF CANCER TO DRIVE MARKET
    4.2 MARKET SHARE,  BY TECHNOLOGY, 2022 VS. 2027 
          FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET IN 2027
    4.3 MARKET SHARE,  BY APPLICATION, 2022 VS. 2027 
          FIGURE 14 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET  IN 2027
    4.4 MARKET SHARE,  BY END USER, 2022 VS. 2027 
          FIGURE 15 HOSPITALS & SPECIALTY CLINICS LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
    4.5 MARKET:  GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 47)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of hematological malignancies
                                TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
                    5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
                    5.2.1.3 Increasing cancer awareness initiatives by global health organizations
           5.2.2 RESTRAINTS
                    5.2.2.1 Complex regulatory frameworks delaying approval of new molecular diagnostics tests
                    5.2.2.2 High cost of minimal residual disease testing kits
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in minimal residual disease testing in emerging countries
                                TABLE 3 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030
           5.2.4 CHALLENGES
                    5.2.4.1 Unclear reimbursement scenario and policies for patients
    5.3 PRICING ANALYSIS 
          TABLE 4 AVERAGE SELLING PRICE OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS (2022)
    5.4 PATENT ANALYSIS 
          FIGURE 18 PATENT ANALYSIS FOR MARKET
           5.4.1 LIST OF KEY PATENTS IN MARKET
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 19 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM/MARKET ANALYSIS 
          FIGURE 21 MARKET: ECOSYSTEM/MARKET ANALYSIS
          TABLE 5 MARKET: ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 DEGREE OF COMPETITION
    5.9 REGULATORY ANALYSIS 
          TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND  OTHER ORGANIZATIONS
          TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.1 NORTH AMERICA
                    5.9.1.1 US
                    5.9.1.2 Canada
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                                TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
                    5.9.3.2 Japan
                                TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
           5.9.4 LATIN AMERICA
                    5.9.4.1 Brazil
                    5.9.4.2 Mexico
           5.9.5 MIDDLE EAST
           5.9.6 AFRICA
    5.10 TRADE ANALYSIS 
           5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS
                     TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY,  2017–2021 (USD MILLION)
                     TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS/KITS, BY COUNTRY,  2017–2021 (USD MILLION)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 
           TABLE 16 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCT MANUFACTURERS
                     FIGURE 22 REVENUE SHIFT IN MARKET
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP THREE APPLICATIONS
                     TABLE 17 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
           5.14.2 BUYING CRITERIA
                     FIGURE 24 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
                     TABLE 18 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
    5.15 CASE STUDY ANALYSIS 
 
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY (Page No. - 71)
    6.1 INTRODUCTION 
          TABLE 19 MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
    6.2 POLYMERASE CHAIN REACTION 
           6.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
                    TABLE 20 MARKET FOR PCR, BY REGION,  2020–2027 (USD MILLION)
    6.3 NEXT-GENERATION SEQUENCING 
           6.3.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO BOOST MARKET
                    TABLE 21 MARKET FOR NGS, BY REGION,  2020–2027 (USD MILLION)
    6.4 FLOW CYTOMETRY 
           6.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO SUPPORT GROWTH
                    TABLE 22 MARKET FOR FLOW CYTOMETRY, BY REGION, 2020–2027 (USD MILLION)
    6.5 OTHER TECHNOLOGIES 
          TABLE 23 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
 
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION (Page No. - 77)
    7.1 INTRODUCTION 
          TABLE 24 MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
    7.2 HEMATOLOGICAL MALIGNANCIES 
          TABLE 25 MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 26 MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2020–2027 (USD MILLION)
           7.2.1 LEUKEMIA
                    TABLE 27 MARKET FOR LEUKEMIA, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 28 MARKET FOR LEUKEMIA, BY TYPE,  2020–2027 (USD MILLION)
                    7.2.1.1 Myeloid leukemia
                               7.2.1.1.1 High prevalence of AML in adults to support growth
                                              TABLE 29 MARKET FOR MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION)
                    7.2.1.2 Lymphocytic leukemia
                               7.2.1.2.1 High incidence of ALL in children to drive market
                                              TABLE 30 MARKET FOR LYMPHOCYTIC LEUKEMIA,  BY REGION, 2020–2027 (USD MILLION)
                    7.2.1.3 Other leukemias
                                 TABLE 31 MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION)
           7.2.2 LYMPHOMA
                    TABLE 32 MARKET FOR LYMPHOMA, BY REGION,  2020–2027 (USD MILLION)
                    TABLE 33 MARKET FOR LYMPHOMA, BY TYPE,  2020–2027 (USD MILLION)
                    7.2.2.1 Non-Hodgkin lymphoma
                               7.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
                                              TABLE 34 MARKET FOR NON-HODGKIN LYMPHOMA,  BY REGION, 2020–2027 (USD MILLION)
                    7.2.2.2 Hodgkin lymphoma
                               7.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel MRD testing
                                              TABLE 35 MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION)
    7.3 SOLID TUMORS 
           7.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
                    TABLE 36 MARKET FOR SOLID TUMORS, BY REGION,  2020–2027 (USD MILLION)
    7.4 OTHER APPLICATIONS 
          TABLE 37 MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
 
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER (Page No. - 87)
    8.1 INTRODUCTION 
          TABLE 38 MARKET, BY END USER,  2020–2027 (USD MILLION)
    8.2 HOSPITALS & SPECIALTY CLINICS 
           8.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
                    TABLE 39 MARKET FOR HOSPITALS & SPECIALTY CLINICS,  BY REGION, 2020–2027 (USD MILLION)
    8.3 DIAGNOSTIC LABORATORIES 
           8.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
                    TABLE 40 MARKET FOR DIAGNOSTIC LABORATORIES,  BY REGION, 2020–2027 (USD MILLION)
    8.4 ACADEMIC & RESEARCH INSTITUTES 
           8.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
                    TABLE 41 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
    8.5 OTHER END USERS 
          TABLE 42 MARKET FOR OTHER END USERS, BY REGION,  2020–2027 (USD MILLION)
 
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION (Page No. - 92)
    9.1 INTRODUCTION 
          TABLE 43 MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 25 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
          TABLE 44 NORTH AMERICA: MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 45 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 46 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
          TABLE 47 NORTH AMERICA: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Increasing prevalence of cancer to drive market
                                TABLE 48 US: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 49 US: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 50 US: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Availability of various cancer screening programs to support market growth
                                TABLE 51 CANADA: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 52 CANADA: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 53 CANADA: MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 54 EUROPE: INCIDENCE OF LEUKEMIA, BY COUNTRY, 2020–2035
          TABLE 55 EUROPE: MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 56 EUROPE: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 57 EUROPE: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
          TABLE 58 EUROPE: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Government support for research funding to support MRD testing market
                                TABLE 59 GERMANY: CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 60 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 61 GERMANY: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 62 GERMANY: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Increasing number of diagnostic laboratories to propel market growth
                                TABLE 63 UK: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 64 UK: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 65 UK: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Rising R&D expenditure in France to drive market
                                TABLE 66 FRANCE: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 67 FRANCE: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 68 FRANCE: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Favorable funding scenario to drive market
                                TABLE 69 ITALY: CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 70 ITALY: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 71 ITALY: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 72 ITALY: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Consolidation of laboratories in Spain to support market growth
                                TABLE 73 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 74 SPAIN: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 75 SPAIN: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 76 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 77 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 78 REST OF EUROPE: MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
          TABLE 79 ASIA PACIFIC: MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
          TABLE 80 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
          TABLE 81 ASIA PACIFIC: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
          TABLE 82 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing public access to advanced healthcare facilities to drive market
                                TABLE 83 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 84 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 85 CHINA: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 86 CHINA: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Universal healthcare reimbursement policy to support market growth
                                TABLE 87 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020
                                TABLE 88 JAPAN: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 89 JAPAN: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 90 JAPAN: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Increasing private and public investments in healthcare system to drive market
                                TABLE 91 INDIA: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                                TABLE 92 INDIA: MARKET, BY APPLICATION,  2020–2027 (USD MILLION)
                                TABLE 93 INDIA: MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 94 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2019
                    TABLE 95 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 96 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 97 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
                    TABLE 98 LATIN AMERICA: MARKET, BY TECHNOLOGY,  2020–2027 (USD MILLION)
                    TABLE 99 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 100 LATIN AMERICA: MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
                    TABLE 101 MIDDLE EAST & AFRICA: MARKET,  BY TECHNOLOGY, 2020–2027 (USD MILLION)
                    TABLE 102 MIDDLE EAST & AFRICA: MARKET,  BY APPLICATION, 2020–2027 (USD MILLION)
                    TABLE 103 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 124)
     10.1 OVERVIEW 
     10.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN 
             10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
                        TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MARKET
     10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MARKET
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 28 MARKET SHARE, BY KEY PLAYER (2021)
             TABLE 105 MARKET: DEGREE OF COMPETITION
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 LIST OF EVALUATED VENDORS
             10.5.2 STARS
             10.5.3 EMERGING LEADERS
             10.5.4 PERVASIVE PLAYERS
             10.5.5 PARTICIPANTS
                        FIGURE 29 MARKET: COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS, 2021
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2021) 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 30 MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2021
     10.7 COMPETITIVE BENCHMARKING 
             10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
                        FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS
                        TABLE 106 MARKET: REGIONAL FOOTPRINT OF COMPANIES
                        TABLE 107 MARKET: PRODUCT & SERVICE FOOTPRINT OF COMPANIES
                        TABLE 108 MARKET: DETAILED LIST OF KEY STARTUPS/SMES
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 109 KEY PRODUCT LAUNCHES
             10.8.2 DEALS
                        TABLE 110 KEY DEALS
 
11 COMPANY PROFILES (Page No. - 137)
     11.1 KEY PLAYERS 
(Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats)*
             11.1.1 ADAPTIVE BIOTECHNOLOGIES
                        TABLE 111 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021)
             11.1.2 ARCHERDX (INVITAE CORPORATION)
                        TABLE 112 ARCHERDX (INVITAE CORPORATION): BUSINESS OVERVIEW
                        FIGURE 33 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2021)
             11.1.3 ASURAGEN, INC.
                        TABLE 113 ASURAGEN, INC.: BUSINESS OVERVIEW
             11.1.4 BIO-RAD LABORATORIES, INC.
                        TABLE 114 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             11.1.5 F. HOFFMANN-LA ROCHE AG
                        TABLE 115 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 35 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
             11.1.6 GUARDANT HEALTH, INC.
                        TABLE 116 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
                        FIGURE 36 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
             11.1.7 MOLECULARMD (SUBSIDIARY OF ICON PLC)
                        TABLE 117 MOLECULAR MD (SUBSIDIARY OF ICON PLC): BUSINESS OVERVIEW
                        FIGURE 37 MOLECULAR MD (ICON PLC): COMPANY SNAPSHOT (2021)
             11.1.8 INVIVOSCRIBE, INC.
                        TABLE 118 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW
             11.1.9 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 119 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
             11.1.10 NATERA, INC.
                        TABLE 120 NATERA, INC.: BUSINESS OVERVIEW
                        FIGURE 39 NATERA, INC.: COMPANY SNAPSHOT (2021)
             11.1.11 SYSMEX CORPORATION
                        TABLE 121 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
     11.2 OTHER PLAYERS 
             11.2.1 NEOGENOMICS LABORATORIES
             11.2.2 OPKO HEALTH, INC.
             11.2.3 GENETRON HEALTH
             11.2.4 QUEST DIAGNOSTICS, INC.
             11.2.5 ARUP LABORATORIES INC.
             11.2.6 MISSION BIO, INC.
             11.2.7 CERGENTIS B.V.
 
*Details on Business overview, Products offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 173)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the minimal residual disease testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Minimal Residual Disease Testing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the minimal residual disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Global minimal residual disease testing market Size: Top-Down Approach

Minimal Residual Disease Testing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global minimal residual disease testing market by technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the market
  • To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Country Information

Minimal residual disease testing market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa

Company profiles

  • Additional five company profiles of players operating in the minimal residual disease testing market.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 8516
Published ON
Dec, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Minimal Residual Disease Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback